These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22698664)

  • 1. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.
    Torres B; Ruoho AE
    Neuroscience; 2014 Feb; 259():194-202. PubMed ID: 24321511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotransmitter recognition by human vesicular monoamine transporter 2.
    Im D; Jormakka M; Juge N; Kishikawa JI; Kato T; Sugita Y; Noda T; Uemura T; Shiimura Y; Miyaji T; Asada H; Iwata S
    Nat Commun; 2024 Sep; 15(1):7661. PubMed ID: 39284862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
    Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
    J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters.
    Black CA; Bucher ML; Bradner JM; Jonas L; Igarza K; Miller GW
    Chem Res Toxicol; 2021 May; 34(5):1256-1264. PubMed ID: 33378168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
    Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
    Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
    Vergo S; Johansen JL; Leist M; Lotharius J
    Brain Res; 2007 Dec; 1185():18-32. PubMed ID: 18028884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
    Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
    J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.
    Guillot TS; Miller GW
    Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
    Dalton MP; Cheng MH; Bahar I; Coleman JA
    Elife; 2024 Mar; 12():. PubMed ID: 38517752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.
    Wang Y; Zhang P; Chao Y; Zhu Z; Yang C; Zhou Z; Li Y; Long Y; Liu Y; Li D; Wang S; Qu Q
    Cell Res; 2024 Jan; 34(1):47-57. PubMed ID: 38163846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
    Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).
    Hu G; Henke A; Karpowicz RJ; Sonders MS; Farrimond F; Edwards R; Sulzer D; Sames D
    ACS Chem Biol; 2013 Sep; 8(9):1947-54. PubMed ID: 23859623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters.
    Mulvihill KG
    Neurochem Int; 2019 Jan; 122():94-105. PubMed ID: 30465801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.